Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

10.70 -0.54 (-4.80%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	547,479
Open	10.75
Bid (Size)	10.74 (300)
Ask (Size)	11.10 (4,000)
Prev. Close	11.24
Today's Range	10.63 - 11.11
52wk Range	6.280 - 20.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)

April 13, 2026

As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche...

Via Finterra

Telix and Regeneron Announce Strategic Radiopharma Collaboration

April 13, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Performance

YTD	+40.4%	+40.4%
1 Month	+36.0%	+36.0%
3 Month	+41.7%	+41.7%
6 Month	+12.2%	+12.2%
1 Year	-36.5%	-36.5%

More News

Regeneron and Telix Announce Strategic Radiopharma Collaboration

April 13, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Accepts NDA for TLX101-Px (Pixclara®)

April 09, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Telix Strengthens Board with Additional Director Appointments

April 08, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

April 06, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Telix Appoints David Gill as Non-Executive Director

April 01, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

March 15, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

March 09, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Investor Education Webinar

March 01, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging

February 27, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth ↗

February 26, 2026

Via The Motley Fool

Telix to Participate in Oppenheimer and TD Cowen Conferences

February 20, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

February 19, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

February 17, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Telix Full Year Results 2025 Investor Webcast Notification

February 03, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

January 20, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

January 16, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights

January 09, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026

January 09, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX

January 08, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

January 08, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Deadline Soon: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

January 08, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm

January 08, 2026

From Schall Law

Via GlobeNewswire

Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference

January 08, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Frequently Asked Questions

Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?

Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.

What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?

Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?

The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market

What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?

The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 10.70

When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?

The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 04/14/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.